Current Report Filing (8-k)
April 27 2020 - 5:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): April 22, 2020
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
NEVADA
|
000-54014
|
20-5093315
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
343 Allerton Ave.
South San Francisco, California 94090
|
(Address of principal executive offices)
|
(650) 577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d -2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common
Stock, par value $0.001 per share
|
VTGN
|
Nasdaq
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2)
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act ☐
Item 1.01 Entry into a Material Definitive Agreement.
The
information set forth below under Item 2.03 is hereby incorporated
by reference into this Item 1.01.
Item 2.03 Creation of a Direct Financial Obligation or an
Obligation Under an Off-Balance Sheet Arrangement of a
Registrant.
On April 22, 2020, VistaGen Therapeutics, Inc.
(the “Company”) received net proceeds of approximately
$224,000 from a potentially forgivable loan from the U. S. Small
Business Administration (“SBA”) pursuant to the Paycheck Protection
Program (“PPP”) enacted by Congress under the of the
Coronavirus Aid, Relief, and Economic Security Act (15 U.S.C.
636(a)(36)) (the “CARES Act”) administered by the SBA (the
“PPP
Loan”). To facilitate the
PPP Loan, the Company entered into a Note Payable Agreement with
Silicon Valley Bank as lender (the “Lender”) (the “PPP Loan
Agreement”).
The
PPP Loan provides for working capital to the Company and will
mature on April 22, 2022. However, under the CARES Act and the PPP
Loan Agreement, all payments of both principal and interest will be
deferred until at least October 22, 2020. The PPP Loan will accrue
interest at a rate of 1.00% per annum, and interest will continue
to accrue throughout the period the PPP Loan is outstanding, or
until it is forgiven. The CARES Act (including the guidance issued
by SBA and U.S. Department of the Treasury related thereto)
provides that all or a portion of the PPP Loan may be forgiven upon
request from the Company to Lender, subject to requirements in the
PPP Loan Agreement and the CARES Act. Although no assurances can be
given, the Company currently believes it will be able to satisfy
the applicable requirements for forgiveness of the PPP Loan and
that the PPP Loan will be forgiven in full.
The
foregoing summary of the PPP Loan is qualified in its entirety by
reference to the PPP Loan Agreement, which is attached as Exhibit
10.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Index
Exhibit No.
|
|
Description
|
|
|
|
|
|
Note
Payable Agreement by and between VistaGen Therapeutics, Inc. and
Silicon Valley Bank, dated April 22, 2020.
|
Signatures
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
VistaGen
Therapeutics, Inc.
|
|
|
|
Date:
April 27, 2020
|
By:
|
/s/ Shawn K. Singh
|
|
|
Shawn
K. Singh
Chief
Executive Officer
|
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024